EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016–2023)

Xiaoqiang Li, Hongmei Xu, Cai Wang, Ruiqiu Zhao, Jiaying Wu, Hui Yu, Chuanqing Wang, Pan Fu, Jikui Deng, Chunzhen Hua, Yinghu Chen, Mingming Zhou und 10 weitere

Frontiers in Cellular and Infection Microbiology · 20.10.2025 · 15

DOI: 10.3389/fcimb.2025.1685606 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 20.10.2025. Verfasst von Xiaoqiang Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disord…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Carbapenems, COVID-19, Bacteremia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study investigated the long-term trends in the distribution and antibiograms of ESKAPEEc pathogens in neonatal and pediatric bloodstream infections (BSIs), shifts in minimum inhibitory concentration (MIC) of vancomycin and linezolid in Staphylococcus aureus , along with the changing patterns of antimicrobial resistance phenotypes over time in China. This work provides a reference for the prevention and treatment of pediatric BSIs.

Methods

A multicenter retrospective surveillance study was carried out from 2016 to 2023 at 12 tertiary pediatric hospitals across nine provinces and autonomous regions in China. The collected data were analyzed using GraphPad Prism 8 and WHONET 5.6. Temporal variations and linear trends were evaluated using chi-square or Fisher’s exact tests.

Results

A total of 10,051 ESKAPEEc strains accounted for 22.5% (10,051/44,675) of all BSIs, with 32.3% from neonatal BSIs and 67.7% from pediatric BSIs. The detection rate of ESKAPEEc pathogens increased for post the coronavirus disease 2019 (COVID-19) compared to the pre-COVID-19. Carbapenem resistance levels were 5.5% in Escherichia coli , 28.0% in Klebsiella pneumoniae , 16.0% in Enterobacter cloacae , 12.5% in Pseudomonas aeruginosa and 38.5% in Acinetobacter baumannii . Both Staphylococcus aureus and Enterococcus faecium remained fully susceptible to vancomycin and linezolid. Between 2016–2019 and 2020–2023, resistance to ceftazidime and gentamicin decreased in Escherichia coli and Klebsiella pneumoniae while resistance to imipenem and meropenem increased. Acinetobacter baumannii exhibited reduced resistance to most antibiotics except cefotaxime, levofloxacin and amikacin. Staphylococcus aureus displayed a declining resistance to macrolides and aminoglycosides but increasing resistance to fluoroquinolones, whereas Enterococcus faecium exhibited reduced resistance to all tested antibiotics. Compared to neonatal BSIs, Klebsiella pneumoniae from pediatric BSIs exhibited lower resistance to all β-lactams especially carbapenems (32.3% vs. 15.0%) while Acinetobacter baumannii displayed higher resistance to all tested agents. Methicillin-susceptible Staphylococcus aureus (MSSA) strains had lower vancomycin MIC ≥2 μg/mL levels compared to methicillin-resistant Staphylococcus aureus (MRSA) strains. Significant temporal differences were observed in MRSA isolates with linezolid MIC ≥2 μg/mL but not in MSSA isolates. The MIC 50 of vancomycin in MRSA strains was either equal to or higher than in MSSA strains from 2016 to 2022. The most frequently detected bacteria in carbapenem resistance, extended-spectrum cephalosporin resistance, fluoroquinolone resistance and aminoglycoside resistance were Acinetobacter baumannii , Klebsiella pneumoniae , Escherichia coli and Acinetobacter baumannii respectively.

Conclusions

The incidence of ESKAPEEc in BSIs has increased, and the rising resistance to imipenem and meropenem in Escherichia coli and Klebsiella pneumoniae underscores the need for continued surveillance. Carbapenems remain effective against Gram-negative ESKAPEEc, while vancomycin and linezolid remain effective against Gram-positive ESKAPEEc. Age-stratified strategies are essential to manage carbapenem-resistant Klebsiella pneumoniae in neonatal BSIs and carbapenem-resistant Acinetobacter baumannii in pediatric BSIs. The MIC values for vancomycin in MRSA strains remained stable over time, whereas a decreasing susceptibility trend to vancomycin in MSSA strains and linezolid MIC shifts were not observed. Our findings are expected to provide to treatment of bloodstream infections in children and evidence on best practices and resource sharing for policy consideration to healthcare providers at the local and international levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCarbapenemsCOVID-19BacteremiaHumansChinaRetrospective StudiesMicrobial Sensitivity TestsChildInfant, NewbornInfantChild, PreschoolDrug Resistance, BacterialVancomycinLinezolidFemaleMaleStaphylococcus aureusSARS-CoV-2East Asian People

Stichwörter der Autor:innen

ESKAPEEcantimicrobial resistancebloodstream infectionsdriftneonatalpediatrictime trend

Substanzen

Anti-Bacterial AgentsCarbapenemsVancomycinLinezolid

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Dis…
  • Infectious Disease Department, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorde…
  • Infectious Disease Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
  • Department of Clinical Microbiology Laboratory, Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
  • Infectious Disease Department, Shenzhen Children's Hospital, Shenzhen, China.
  • Infectious Disease Department, Children's Hospital of Zhejiang University, Hangzhou, China.

Zitieren

APA

Li, X., Xu, H., Wang, C., Zhao, R., Wu, J., Yu, H., Wang, C., Fu, P., Deng, J., Hua, C., Chen, Y., Zhou, M., Zhang, T., Zhang, H., Chen, Y., Wang, S., Cao, Q., Deng, H., Cai, H., …, & Jing, C. (2025). COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016–2023). Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1685606

Vancouver

Li X, Xu H, Wang C, Zhao R, Wu J, Yu H, et al. COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016–2023). Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1685606

BibTeX
@article{Li2025,
  author = {Li, Xiaoqiang and Xu, Hongmei and Wang, Cai and Zhao, Ruiqiu and Wu, Jiaying and Yu, Hui and Wang, Chuanqing and Fu, Pan and Deng, Jikui and Hua, Chunzhen and Chen, Yinghu and Zhou, Mingming and Zhang, Ting and Zhang, Hong and Chen, Yiping and Wang, Shifu and Cao, Qing and Deng, Huiling and Cai, Huijun and Hao, Jianhua and Zhou, Yuyang and Jing, Chunmei},
  title = {COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016–2023)},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1685606}
}
Kostenlos starten →